GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis
NASDAQ:GMAB - Nasdaq - US3723032062 - ADR - Currency: USD
Taking everything into account, GMAB scores 7 out of 10 in our fundamental rating. GMAB was compared to 568 industry peers in the Biotechnology industry. GMAB scores excellent points on both the profitability and health parts. This is a solid base for a good stock. GMAB has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes GMAB very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year GMAB was profitable.
GMAB had a positive operating cash flow in the past year.
GMAB had positive earnings in each of the past 5 years.
GMAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
GMAB has a better Return On Assets (17.12%) than 97.36% of its industry peers.
With an excellent Return On Equity value of 21.38%, GMAB belongs to the best of the industry, outperforming 96.83% of the companies in the same industry.
With an excellent Return On Invested Capital value of 13.92%, GMAB belongs to the best of the industry, outperforming 96.83% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for GMAB is in line with the industry average of 14.25%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.12% | ||
| ROE | 21.38% | ||
| ROIC | 13.92% |
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
1.3 Margins
GMAB's Profit Margin of 36.44% is amongst the best of the industry. GMAB outperforms 98.59% of its industry peers.
In the last couple of years the Profit Margin of GMAB has declined.
With an excellent Operating Margin value of 32.18%, GMAB belongs to the best of the industry, outperforming 98.42% of the companies in the same industry.
GMAB's Operating Margin has declined in the last couple of years.
The Gross Margin of GMAB (95.42%) is better than 94.01% of its industry peers.
In the last couple of years the Gross Margin of GMAB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.18% | ||
| PM (TTM) | 36.44% | ||
| GM | 95.42% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
GMAB has less shares outstanding than it did 1 year ago.
GMAB has less shares outstanding than it did 5 years ago.
The debt/assets ratio for GMAB is higher compared to a year ago.
2.2 Solvency
GMAB has an Altman-Z score of 7.75. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
GMAB's Altman-Z score of 7.75 is amongst the best of the industry. GMAB outperforms 86.80% of its industry peers.
GMAB has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
GMAB has a Debt to FCF ratio of 0.14. This is amongst the best in the industry. GMAB outperforms 97.01% of its industry peers.
GMAB has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
GMAB has a Debt to Equity ratio (0.03) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 7.75 |
ROIC/WACC2.06
WACC6.77%
2.3 Liquidity
GMAB has a Current Ratio of 5.25. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.25, GMAB perfoms like the industry average, outperforming 56.34% of the companies in the same industry.
A Quick Ratio of 5.24 indicates that GMAB has no problem at all paying its short term obligations.
GMAB has a Quick ratio (5.24) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.25 | ||
| Quick Ratio | 5.24 |
3. Growth
3.1 Past
GMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.75%, which is quite impressive.
Measured over the past years, GMAB shows a very strong growth in Earnings Per Share. The EPS has been growing by 29.12% on average per year.
Looking at the last year, GMAB shows a very strong growth in Revenue. The Revenue has grown by 30.67%.
The Revenue has been growing by 32.03% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)83.75%
EPS 3Y38.63%
EPS 5Y29.12%
EPS Q2Q%516.75%
Revenue 1Y (TTM)30.67%
Revenue growth 3Y36.75%
Revenue growth 5Y32.03%
Sales Q2Q%37.69%
3.2 Future
Based on estimates for the next years, GMAB will show a small growth in Earnings Per Share. The EPS will grow by 7.42% on average per year.
GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.53% yearly.
EPS Next Y-13.59%
EPS Next 2Y1.9%
EPS Next 3Y9.01%
EPS Next 5Y7.42%
Revenue Next Year17.9%
Revenue Next 2Y15.9%
Revenue Next 3Y12.99%
Revenue Next 5Y11.53%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 10.66 indicates a reasonable valuation of GMAB.
Based on the Price/Earnings ratio, GMAB is valued cheaper than 97.71% of the companies in the same industry.
When comparing the Price/Earnings ratio of GMAB to the average of the S&P500 Index (28.29), we can say GMAB is valued rather cheaply.
GMAB is valuated correctly with a Price/Forward Earnings ratio of 12.35.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 96.30% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of GMAB to the average of the S&P500 Index (21.08), we can say GMAB is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.66 | ||
| Fwd PE | 12.35 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 98.59% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, GMAB is valued cheaply inside the industry as 97.54% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.12 | ||
| EV/EBITDA | 7.05 |
4.3 Compensation for Growth
GMAB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.37
EPS Next 2Y1.9%
EPS Next 3Y9.01%
5. Dividend
5.1 Amount
No dividends for GMAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
20.04
+0.49 (+2.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners40.98%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap12.63B
Analysts77.33
Price Target136.69 (582.09%)
Short Float %0.38%
Short Ratio1.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)58.93%
Min EPS beat(2)-11.29%
Max EPS beat(2)129.15%
EPS beat(4)3
Avg EPS beat(4)47.14%
Min EPS beat(4)-11.29%
Max EPS beat(4)129.15%
EPS beat(8)5
Avg EPS beat(8)18.82%
EPS beat(12)8
Avg EPS beat(12)26.25%
EPS beat(16)11
Avg EPS beat(16)44.04%
Revenue beat(2)0
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-4.27%
Max Revenue beat(2)-1.54%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-4.27%
Max Revenue beat(4)6.12%
Revenue beat(8)6
Avg Revenue beat(8)1.47%
Revenue beat(12)10
Avg Revenue beat(12)3.15%
Revenue beat(16)14
Avg Revenue beat(16)4.46%
PT rev (1m)-23.03%
PT rev (3m)-23.03%
EPS NQ rev (1m)15.4%
EPS NQ rev (3m)80.16%
EPS NY rev (1m)3.42%
EPS NY rev (3m)5.61%
Revenue NQ rev (1m)-0.83%
Revenue NQ rev (3m)4.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.66 | ||
| Fwd PE | 12.35 | ||
| P/S | 3.86 | ||
| P/FCF | 11.12 | ||
| P/OCF | 10.68 | ||
| P/B | 2.26 | ||
| P/tB | 3.81 | ||
| EV/EBITDA | 7.05 |
EPS(TTM)1.88
EY9.38%
EPS(NY)1.62
Fwd EY8.1%
FCF(TTM)1.8
FCFY8.99%
OCF(TTM)1.88
OCFY9.36%
SpS5.2
BVpS8.86
TBVpS5.27
PEG (NY)N/A
PEG (5Y)0.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.12% | ||
| ROE | 21.38% | ||
| ROCE | 17.1% | ||
| ROIC | 13.92% | ||
| ROICexc | 29.06% | ||
| ROICexgc | 124.64% | ||
| OM | 32.18% | ||
| PM (TTM) | 36.44% | ||
| GM | 95.42% | ||
| FCFM | 34.69% |
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
ROICexc(3y)69.46%
ROICexc(5y)81.57%
ROICexgc(3y)103.42%
ROICexgc(5y)105.51%
ROCE(3y)18.66%
ROCE(5y)20.11%
ROICexcg growth 3Y22.47%
ROICexcg growth 5Y10.4%
ROICexc growth 3Y-22.82%
ROICexc growth 5Y-14.86%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score5
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.13 | ||
| Cap/Depr | 73.61% | ||
| Cap/Sales | 1.41% | ||
| Interest Coverage | 197.91 | ||
| Cash Conversion | 105.87% | ||
| Profit Quality | 95.19% | ||
| Current Ratio | 5.25 | ||
| Quick Ratio | 5.24 | ||
| Altman-Z | 7.75 |
F-Score5
WACC6.77%
ROIC/WACC2.06
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)83.75%
EPS 3Y38.63%
EPS 5Y29.12%
EPS Q2Q%516.75%
EPS Next Y-13.59%
EPS Next 2Y1.9%
EPS Next 3Y9.01%
EPS Next 5Y7.42%
Revenue 1Y (TTM)30.67%
Revenue growth 3Y36.75%
Revenue growth 5Y32.03%
Sales Q2Q%37.69%
Revenue Next Year17.9%
Revenue Next 2Y15.9%
Revenue Next 3Y12.99%
Revenue Next 5Y11.53%
EBIT growth 1Y30.18%
EBIT growth 3Y33.83%
EBIT growth 5Y21.83%
EBIT Next Year35.31%
EBIT Next 3Y25.5%
EBIT Next 5Y13.95%
FCF growth 1Y6.61%
FCF growth 3Y55.76%
FCF growth 5Y43.79%
OCF growth 1Y5.3%
OCF growth 3Y51.65%
OCF growth 5Y42.43%